Pharmafile Logo
Pharmafocus logo
Advanced Search

Glyxambi

Showing 3 posts of 3 posts found.

Boehringer assures future growth following sales drop

April 23, 2015
Sales and Marketing Boehringer, COPD, Glyxambi, Striverdi Respimat, empagliflozin, empagliflozin/linagliptin, financials, full year, jardiance, nintedanib, ofev, olodaterol, results

Boehringer says it is positioned for future growth in the wake of filing a decline in profit for 2014 and …

News

Lilly and Boehringer diabetes drug sees US launch

March 24, 2015
Sales and Marketing Boehringer, Glyxambi, Tradjenta, diabetes, empagliflozin/linagliptin, lilly, linagliptin

Lilly and Boehringer Ingelheim’s combo diabetes drug Glyxambi is now available to treat adult patients in the US. Glyxambi (empagliflozin/linagliptin) …

News
Glyxambi image

Boehringer and Lilly score FDA yes for Glyxambi

February 3, 2015
Sales and Marketing Boehringer, FDA, Glyxambi, Tradjenta, empagliflozin, jardiance, lilly, linagliptin

The FDA has approved Glyxambi (empagliflozin/linagliptin), which has become the first combination of two diabetes drugs in their different classes …

News
The Gateway to Local Adoption Series

Latest content

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026

Alvotech appoints Lisa Graver as CEO

February 3, 2026

HonorHealth Research Institute announces first patient dosed with new stroke treatment

February 2, 2026

Accord Healthcare appoints Paul Burden as Associate Vice President and Country Head UK

February 2, 2026

Historic UN declaration supporting mental health – treatment to be given similar priority to chronic diseases

January 30, 2026